文献速递淋巴瘤

晚期皮肤淋巴瘤的新预后指数(CLIPI)可实现精确的患者风险分层

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.
PubMed 文献 · Blood · 2025-01-01

PROCLIPI研究于2015年在46家国际MF/SS专家中心启动,前瞻性收集新诊断MF/SS患者数据,纳入552例晚期MF/SS患者。诊断时N3状态(P < .001)、年龄>60岁(P < .001)、血清乳酸脱氢酶升高(P = .005)和皮肤大细胞转化(P = .006)与生存显著更差相关。将4个独立危险因素建模为CLIPI后,低、中、高风险组5年OS分别为63.3%、44.7%、18.3%。

要点

  • PROCLIPI研究纳入552例晚期MF/SS患者,前瞻性构建CLIPI。
  • 诊断时N3状态、年龄>60岁、血清乳酸脱氢酶升高和皮肤大细胞转化为独立危险因素。
  • CLIPI低、中、高风险组5年OS分别为63.3%、44.7%、18.3%。

核心结论

  • 晚期MF/SS患者5年生存率低,分期增加与生存恶化无关。
  • CLIPI将患者分为风险组,可能改善结局并有助于最佳治疗选择。

研究设计与样本

  • PROCLIPI(前瞻性皮肤淋巴瘤国际预后指数)研究于2015年在46家国际MF/SS专家中心启动,前瞻性收集新诊断MF/SS患者的预设数据集,以确定皮肤淋巴瘤IPI(CLIPI)。
  • 共招募552例晚期MF/SS患者。
  • 试验在www.ClinicalTrials.gov注册,注册号为#NCT02848274。

主要发现

  • 5年OS:IIB期为50.0%,IIIA期为64.8%,IIIB期为43.9%,IVA1期为50.8%,IVA2期为25.9%,IVB期为36.9%。
  • 诊断时与生存显著更差相关的因素:N3状态(P < .001)、年龄>60岁(P < .001)、血清乳酸脱氢酶升高(P = .005)、皮肤大细胞转化(P = .006)。
  • 将4个独立危险因素建模为CLIPI后,高风险组较低风险组OS更差(P < .001),高风险组较中风险组OS更差(P = .002),中风险组较低风险组OS更差(P = .010)。
  • 5年OS在低、中、高风险组分别为63.3%、44.7%、18.3%。

关键数值与推荐

  • CLIPI基于诊断时4个独立危险因素:N3状态(P < .001)、年龄>60岁(P < .001)、血清乳酸脱氢酶升高(P = .005)、皮肤大细胞转化(P = .006)。
  • CLIPI风险分组间OS比较:高风险组较低风险组(P < .001),高风险组较中风险组(P = .002),中风险组较低风险组(P = .010)。

临床怎么用

  • 作者认为,使用CLIPI将患者分层为风险组可能改善结局并有助于最佳治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of <5 years. Studies have found the current staging (IA-IVB) is inadequate for risk stratification. The PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study was launched in 2015 at 46 international expert MF/SS centers, prospectively collecting predefined data sets in patients with newly diagnosed MF/SS, to determine a cutaneous lymphoma IPI (CLIPI). Five hundred fifty-two patients with advanced stage MF/SS were recruited. The 5-year OS was 50.0% for stage IIB, 64.8% for stage IIIA, 43.9% for stage IIIB, 50.8% for stage IVA1, 25.9% for stage IVA2, and 36.9% for stage IVB. Factors at diagnosis associated with a significantly worse survival were N3 status (P < .001), age >60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell transformation in skin (P = .006). Modeling these 4 independent risk factors into a CLIPI found that there was a worse OS in high- vs low-risk (P < .001), high- vs intermediate-risk (P = .002) and intermediate- vs low-risk (P = .010) groups. Five-year OS was 63.3%, 44.7%, and 18.3% in the low-, intermediate-, and high-risk groups, respectively. In this advanced stage cohort there was a low 5-year survival and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into risk groups has the potential to improve outcomes and aid optimal treatment selection. This trial was registered at www.ClinicalTrials.gov as #NCT02848274.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Scarisbrick JJ, Quaglino P, Whittaker S, et al. A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification. Blood. 2025. PMID: 40663780. doi:10.1182/blood.2025029628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。